Recent findings have demonstrated that most AML cells express both TNF-α and IL-1β, so the combined inhibition of TNF-α and IL-1β has been shown to synergize with NF-κB, effectively eliminating the LSC pool ex vivo and exhibiting significant anti-leukemic activity in in vivo mouse models [97]. The gene discussed is NFKB1; the disease is acute myeloid leukemia.